{"id":"W2134392974","doi":"10.1200/jco.2012.48.3552","title":"Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":494,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"West China Hospital, Sichuan University; BC Cancer Agency; Novartis Pharma; Chugai Pharmaceutical; Ruijin Hospital; Hebei Medical University; Nanfang Hospital; Institut Gustave-Roussy; School of Medicine, Shanghai Jiao Tong University; Peking University; KU Leuven; Sichuan University; Universitair Ziekenhuis Gent; Sun Yat-sen University; China Medical University; Fudan University; McGill University; Sir Run Run Shaw Hospital; Shanghai Jiao Tong University; Harbin Medical University; Sanofi; Soochow University; GlaxoSmithKline","keywords":"Everolimus; Medicine; Ramucirumab; Internal medicine; Hazard ratio; Clinical endpoint; Adverse effect; Cancer; Placebo; Phases of clinical research; Gastroenterology; Chemotherapy; Surgery; Oncology; Clinical trial; Confidence interval; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1285665799292115,"score_gpt":0.4762735821499621,"score_spread":0.3477070022207507,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}